Background
==========

Neonatal hyperbilirubinemia is caused by abnormal metabolism of bilirubin, and is characterized by a syndrome of skin, mucous membrane, and sclera jaundice \[[@b1-medscimonit-21-3104]\]. While most cases are physiological, when the serum bilirubin concentrations are higher than 12.9 mg/dl in full-term infants and for a prolonged period of time, jaundice is no longer considered physiologic \[[@b2-medscimonit-21-3104],[@b3-medscimonit-21-3104]\]. In pathological hyperbilirubinemia, increased production of bilirubin, deficiency in hepatic uptake, impaired conjugation of bilirubin, and/or increased enterohepatic circulation of bilirubin are observed \[[@b4-medscimonit-21-3104]\]. However, there is no identifiable factor in almost half of cases.

It has been suggested that genetic variation could enhance the risk of neonatal hyperbilirubinemia when coexpressed with other icterogenic conditions \[[@b5-medscimonit-21-3104]--[@b7-medscimonit-21-3104]\]. Among these, uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) was identified to be associated with neonatal hyperbilirubinemia \[[@b8-medscimonit-21-3104],[@b9-medscimonit-21-3104]\]. UGT1A1 is the key rate-limiting enzyme in the liver for bilirubin glucuronidation, which is a clearance mechanism for numerous dietary and environmental chemicals, including bilirubin \[[@b10-medscimonit-21-3104],[@b11-medscimonit-21-3104]\]. The polymorphisms of the UGT1A1 coding region or the promoter may produce structural or functional enzymatic deficiencies, leading to intermittent elevation of unconjugated serum bilirubin, resulting in hyperbilirubinemias known as Gilbert's syndrome (GS) and Crigler-Najjar syndrome (GNS) \[[@b12-medscimonit-21-3104],[@b13-medscimonit-21-3104]\]. Numerous polymorphisms of UGT1A1 have been reported in patients with GS and CNS, including Gly71Arg and TATA promoter \[[@b14-medscimonit-21-3104],[@b15-medscimonit-21-3104]\].

The Gly71Arg (G71R) of the UGT1A1 gene has been reported as a genetic risk factor for GS, which might reduce the activity of the enzyme, and then cause mild unconjugated hyperbilirubinemia \[[@b16-medscimonit-21-3104]--[@b18-medscimonit-21-3104]\]. In addition, the TATA promoter polymorphism has been described as another major cause of neonatal hyperbilirubinemia, which is characterized by an increase of total serum bilirubin as a result of poor enzymatic conjugation by glucuronosyltransferase \[[@b6-medscimonit-21-3104],[@b19-medscimonit-21-3104],[@b20-medscimonit-21-3104]\]. TA sequences in the promoter region vary in length from 5 to 8 repeats, and the (TA)7 (UGT1A1\*28) and (TA)8 homozygotes, when compared with (TA)6 homozygote, (TA)6/(TA)7 or (TA)6/(TA)8 heterozygotes, have been considered as causes of hyperbilirubinemic syndromes. The (TA)7 homozygote leads to a 70% reduction in UGT1A1 expression as compared to the (TA)6 carriers \[[@b21-medscimonit-21-3104]\]. Recent data have also shown that the effects of variants in UGT1A1 gene appear to be variable across populations \[[@b22-medscimonit-21-3104]--[@b24-medscimonit-21-3104]\]. Therefore, we performed a meta-analysis to assess whether the UGT1A1 polymorphisms are associated with neonatal hyperbilirubinemia. We analyzed the Gly71Arg and TATA promoter polymorphisms of UGT1A1 between cases and controls.

Material and Methods
====================

The present meta-analysis was performed according to PRISMA recommendations \[[@b25-medscimonit-21-3104]\]. The PubMed, Cochrane Library, and Embase databases were searched independently by 2 investigators to retrieve relevant studies published from January 1, 1998 to October 31, 2014. The search criteria "hyperbilirubinemia", "UDP-glucuronosyl transferase 1A1 (UGT1A1)", and "polymorphism" were used in text word searches. The "related articles" function was used to broaden the search. The reference lists of the selected articles were also manually examined to find relevant studies that were not discovered during the database searches.

Exclusion criteria
------------------

Exclusion criteria were: A) incomplete raw data, B) repetitive reports, and C) material and methods used were not well described or reliable. We used reliability of the methods for patient selection, molecular typing, and statistical analysis as quality variables to accurately assess the quality measures of interest.

Polymorphisms related to neonatal hyperbilirubinemia were divided into 2 groups according to TATA promoter polymorphism and G71R polymorphism in the UGT1A1 gene. All titles, abstracts, and full papers of potentially relevant studies were assessed for eligibility. When several reports from the same study were published, only the most recent or informative one was included in this meta-analysis. The language was restricted to only English.

Data extraction
---------------

Two investigators extracted all variables and outcomes of interest independently. Disagreements were resolved through discussion and consensus. Data on first author and year of publication, neonatal hyperbilirubinemia definition, country of study, numbers of cases and controls, and UGT1A1 gene polymorphism genotyping information were extracted ([Table 1](#t1-medscimonit-21-3104){ref-type="table"}).

Quality assessment
------------------

The included studies were assessed independently by the 2 reviewers using the Newcastle-Ottawa Scale (NOS) \[[@b26-medscimonit-21-3104]\]. The NOS employs a star rating system to assess quality from 3 broad perspectives of the study: (1) selection of the study groups, (2) comparability of the groups, and (3) identification of the exposure (for case-control studies) or outcome of interest (for cohort studies). Scores ranged from 0 to 9 stars, and studies with 7 or more stars were considered to be of high quality.

Statistical analysis
--------------------

The statistical analysis was performed using meta-analysis software called "Comprehensive Meta Analysis". The strength of the association between UGT1A1 gene polymorphisms and neonatal hyperbilirubinemia risk was calculated with the OR and respective 95% CIs. The significance of the pooled OR was determined by the Z test, and P-values of less than 0.05 were considered significant. Chi-square test was used for assessing the Hardy-Weinberg equilibrium (HWE) of genotypes in the control group of each study. Statistical heterogeneity among studies was assessed with the I2 statistics. This value ranges from 0% (complete consistency) to 100% (complete inconsistency). If the I2 value was more than 50%, the random-effects model was chosen to calculate the pooled OR; otherwise, the fixed-effects model was used. All of the results were presented as forest plots. In the sensitivity analysis, we removed each study sequentially and performed meta-analysis with the rest repeatedly to show how conclusions might be affected. The presence of publication bias was assessed by a visual inspection of a funnel plot and Egger's linear regression test.

Results
=======

Literature search
-----------------

The initial literature search retrieved 322 relevant articles. We excluded 289 articles for not investigating the topic of interest or insufficient data after carefully screening the titles and abstracts. All studies included were in accordance with NOS scale and were therefore defined as high-quality studies. A total of 32 articles with 2455 cases of neonatal hyperbilirubinemia and 4065 controls were included in the meta-analysis. The characteristics of the included studies are summarized in [Table 1](#t1-medscimonit-21-3104){ref-type="table"}. A review of the data extraction revealed 100% agreement between the 2 reviewers.

Main analysis
-------------

Finally, 24 studies focused on the relationship between G71R UGT1A1 polymorphism and neonatal hyperbilirubinemia ([Table 2](#t2-medscimonit-21-3104){ref-type="table"}). [Table 2](#t2-medscimonit-21-3104){ref-type="table"} and [Table 3](#t3-medscimonit-21-3104){ref-type="table"} list the genotyped and allele distributions of the G71R for the cases and controls. Although most research has been in East Asian populations, the A allele does not appear to be different among races. The genotype frequencies of the G/A polymorphism were 80.7% (GG), 17.7% (GA), and 1.6% (AA) in controls, and 72.0% (GG), 23.0% (GA), and 5.0% (AA) in hyperbilirubinemia neonates. The A allele frequencies in the control group was 0.104. For allele level comparison, the A allele was found to be associated with a risk of hyperbilirubinemia in terms of the frequency of allele comparison (A *vs.* G: OR=2.17; 95% CI=1.74--2.72, P \<0.0001). For a dominant model of the A allele, the AG + AA genotypes were associated with the risk for hyperbilirubinemia (AG + AA *vs.* GG, OR=2.25, 95% CI=1.76--2.87, P\<0.0001). For a recessive model of the A allele, the AA homozygote genotype was associated with susceptibility to hyperbilirubinemia (AA *vs.* AG+GG, OR=3.47, 95% CI =2.29--5.28, P \<0.0001, Heterogeneity=0.058) ([Figure 1C](#f1-medscimonit-21-3104){ref-type="fig"}). For the extreme genotype, the AA genotype was associated with the risk for hyperbilirubinemia (AA *vs.* GG, OR=4.01, 95% CI=2.47--6.51, P\<0.0001, Heterogeneity=0.224) ([Figure 1A](#f1-medscimonit-21-3104){ref-type="fig"}) ([Table 3](#t3-medscimonit-21-3104){ref-type="table"}).

Quantitative synthesis showed significant differences in the comparisons of GG *vs.* AA+GA (OR=2.25, P\<0.0001, 95% CI=1.76--2.87, Heterogeneity=0.493) ([Figure 1B](#f1-medscimonit-21-3104){ref-type="fig"}). In addition, comparing the A allele to the G allele in the G71R polymorphism also showed a significant difference (OR=2.17, P \<0.0001, 95% CI=1.74--2.72, Heterogeneity=0.555) ([Figure 1D](#f1-medscimonit-21-3104){ref-type="fig"}).

Nineteen studies focused on the relationships between TATA promoter polymorphism and neonatal hyperbilirubinemia ([Table 4](#t4-medscimonit-21-3104){ref-type="table"}). [Table 4](#t4-medscimonit-21-3104){ref-type="table"} and [Table 5](#t5-medscimonit-21-3104){ref-type="table"} list the genotyped and allele distributions of the TATA promoter polymorphisms for the cases and controls. The genotype frequencies of the TATA polymorphisms were 63.4% (6/6), 31.0% (6/7), and 5.6% (7/7) in controls, and 51.8% (6/6), 32.9% (6/7), and 15.3% (7/7) in hyperbilirubinemia neonates. The (TA)7 allele frequencies in the control group was 0.216. For allele level comparison, the (TA)7 allele was associated with an increased risk of hyperbilirubinemia in terms of the frequency of allele comparison ((TA)7 *vs.* (TA)6, OR=1.51, 95% CI=1.03--2.20, P=0.035, Heterogeneity=89.2%) ([Figure 2D](#f2-medscimonit-21-3104){ref-type="fig"}). For a dominant model of the 6/6 allele, the 6/7+7/7 genotypes were associated with the risk for hyperbilirubinemia (6/7+7/7 *vs.* 6/6, OR=1.56, 95%CI=1.02--2.40, P=0.042, Heterogeneity=85.1%) ([Figure 2B](#f2-medscimonit-21-3104){ref-type="fig"}). For the 7/7 allele, the homozygote genotype was also associated with hyperbilirubinemia (6/7 + 6/6 *vs.* 7/7, OR=2.24, 95% CI=1.29--3.92, P=0.004, Heterogeneity=73.4%) ([Figure 2C](#f2-medscimonit-21-3104){ref-type="fig"}). For the extreme genotype, the 7/7 genotype was associated with the risk for hyperbilirubinemia (7/7 *vs.* 6/6, OR=2.71, 95% CI=1.52--4.82, P=0.001, heterogeneity=70.8%) ([Figure 2A](#f2-medscimonit-21-3104){ref-type="fig"}, [Table 5](#t5-medscimonit-21-3104){ref-type="table"}). Analysis of these studies indicated that the TATA promoter polymorphism also increased the risk of neonatal hyperbilirubinemia.

Discussion
==========

Our meta-analysis showed that both UGT1A1 G71R and TATA promoter polymorphisms are risk factors for developing hyperbilirubinemia in white, black and Asian neonates, which was consistent with some previous studies but conflicted with others. Homozygous or heterozygous G71R and (TA)7 polymorphism were frequent not only in hyperbilirubinemia patients but also in healthy subjects \[[@b27-medscimonit-21-3104],[@b28-medscimonit-21-3104]\]. It has been reported that the high frequency of G71R and (TA) insertion of the UGT1A1 gene are associated with a high incidence of neonatal hyperbilirubinemia \[[@b29-medscimonit-21-3104]--[@b31-medscimonit-21-3104]\]. Sato et al. found that the influence of G71R polymorphism might be overcome by adequate breastfeeding \[[@b32-medscimonit-21-3104]\]. However, contrary to these findings, Mezzacappa et al. did not find any significant effect of the variants on bilirubin levels among the newborns \[[@b20-medscimonit-21-3104],[@b33-medscimonit-21-3104]--[@b37-medscimonit-21-3104]\].

An *in vitro* study verified that the UGT1A1 G71R mutant could decrease UGT1A1 enzymatic activity, which could cause moderately delayed bilirubin elimination \[[@b38-medscimonit-21-3104]\]. Therefore, neonates carrying the G71R UGT1A1 variant may be at risk for hyperbilirubinemia \[[@b18-medscimonit-21-3104]\]. However, some studies found no effect of the polymorphism \[[@b36-medscimonit-21-3104],[@b39-medscimonit-21-3104]\] Therefore, the mechanism of the G71R polymorphism requires further research \[[@b40-medscimonit-21-3104],[@b41-medscimonit-21-3104]\].

The (TA) insertion in the promoter also has been considered be associated with hyperbilirubinemia \[[@b42-medscimonit-21-3104]\]. The A (TA7) TAA allele was reported to be frequently present in GS \[[@b43-medscimonit-21-3104]\]. The extra TA reduced expression of the enzyme, resulting in decreased bilirubin glucuronidation activity \[[@b44-medscimonit-21-3104]\]. The SNP could reduce the promoter activity, which leads to unconjugated nonhemolytic hyperbilirubinemia \[[@b45-medscimonit-21-3104],[@b46-medscimonit-21-3104]\].

The data strongly suggest that UGT1A1 promoter (TA)7 polymorphism influences serum total bilirubin values by increasing heme catabolism as well as decreasing bilirubin conjugation \[[@b23-medscimonit-21-3104]\]. In analogous studies, the (TA)7 variant was associated with modestly higher total serum bilirubin levels and (TA)7 polymorphism in the promoter developed prolonged indirect hyperbilirubinemia \[[@b7-medscimonit-21-3104],[@b47-medscimonit-21-3104],[@b48-medscimonit-21-3104]\]. However, some other studies have failed to demonstrate a clinically significant effect of UGT1A1 TATA promoter variations on hyperbilirubinemia risk \[[@b23-medscimonit-21-3104],[@b49-medscimonit-21-3104]\], such as a southern Brazil study that found the (TA)7 promoter polymorphism of UGT1A1 had no association with hyperbilirubinemia \[[@b50-medscimonit-21-3104]\]. Ultimately, our research showed that (TA)7 promoter polymorphism was associated with increased risk of neonatal hyperbilirubinemia. Some studies have found a synergic effect with the (TA)7TAA promoter and G71R variants on the level of plasma bilirubin \[[@b51-medscimonit-21-3104]\]. By the pathway of influence of the metabolism of heme oxygenase, we can speculate that neonates carrying the Gly71Arg or (TA)7TAA polymorphisms have decreased UGT1A1 activity, which may directly or indirectly increase COHbc and decrease serum conjugated bilirubin fractions \[[@b52-medscimonit-21-3104]\].

The most important limitation of this meta-analysis is the inconsistency of the baseline characteristics (e.g., age, sex, and concomitant disease) between the case and control groups, which might increase the selection bias.

Conclusions
===========

Our meta-analysis suggests that Gly71Arg and (TA)7 promoter polymorphisms in the UGT1A1 gene significantly increase risk of neonatal hyperbilirubinemia.
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###### 

Characteristics of included studies.

  Author (reference)                                  Year   Country         Characteristics of cases                                                                                   Control(n)   Case(n)
  --------------------------------------------------- ------ --------------- ---------------------------------------------------------------------------------------------------------- ------------ ---------
  Akaba et al. \[[@b24-medscimonit-21-3104]\]         1998   Japan           STB \>17 mg/dl                                                                                             101          42
  Maruo et al. \[[@b18-medscimonit-21-3104]\]         1999   Japan           STB \>15 mg/dl                                                                                             50           25
  Yamamoto et al. \[[@b16-medscimonit-21-3104]\]      2002   Japan           STB \>15 mg/dl in the first 7 days                                                                         49           23
  Huang et al. \[[@b14-medscimonit-21-3104]\]         2002   Taiwan, China   STB ≥15 mg/dl within 1 week after birth                                                                    218          123
  Seco et al. \[[@b41-medscimonit-21-3104]\]          2002   Spain           STB \>15 mg/dl                                                                                             115          21
  Ulgenalp et al. \[[@b4-medscimonit-21-3104]\]       2003   Turkey          STB \>12.9 mg/dl                                                                                           35           75
  Takeuchi et al. \[[@b33-medscimonit-21-3104]\]      2004   Japan           STB level \>17 mg/dl                                                                                       71           68
  Huang et al. \[[@b28-medscimonit-21-3104]\]         2004   Taiwan, China   a peak STB ≥20.0 mg/dl in serum within 10 d of birth                                                       100          72
  Sutomo et al. \[[@b34-medscimonit-21-3104]\]        2004   Malaysia        STB \>15 mg/dl at day 3                                                                                    36           32
  Kanai et al. \[[@b51-medscimonit-21-3104]\]         2005   Japan           STB \>15 mg/dl at day 4 and thereafter                                                                     116          29
  Yusoff et al. \[[@b48-medscimonit-21-3104]\]        2005   Malaysia        STB \>15 mg/dl                                                                                             50           55
  Ferraris et al. \[[@b15-medscimonit-21-3104]\]      2006   Italy           STB \>17 mg/dl                                                                                             83           53
  Babaoglu et al. \[[@b21-medscimonit-21-3104]\]      2006   Tukey           STB \>17 mg/dl                                                                                             32           74
  Muslu et al. \[[@b36-medscimonit-21-3104]\]         2006   Turkey          STB \>15mg/dl, \<7d                                                                                        55           107
  Farheen et al. \[[@b26-medscimonit-21-3104]\]       2006   India           UCB ≥1.2 mg/dl                                                                                             95           95
  Wong et al. \[[@b9-medscimonit-21-3104]\]           2007   Malaysia        STB \>15 mg/dl at age 1--2 days or \>17 mg/dl at age 3 days and onward                                     125          74
  Watchko et al. \[[@b6-medscimonit-21-3104]\]        2009   America         STB \>95% high-risk zone                                                                                   299          153
  Chang et al. \[[@b27-medscimonit-21-3104]\]         2009   Taiwan, China   STB \>5.9 mg/dl beyond 28 days of age                                                                      90           35
  Prachukthum et al. \[[@b39-medscimonit-21-3104]\]   2009   Thailand        STB \>95% as defined by the Bhutani nomogram                                                               86           91
  Agrawal et al. \[[@b7-medscimonit-21-3104]\]        2009   India           STB \>18 mg/dl                                                                                             50           69
  Ergin et al. \[[@b19-medscimonit-21-3104]\]         2010   Turkey          STB ≥17 mg/dl                                                                                              54           50
  Kilic et al. \[[@b40-medscimonit-21-3104]\]         2010   Turkey          STB \>12.9 mg/dl, or TSB \>8.8 mg/dl at day 14                                                             23           47
  Narter et al. \[[@b38-medscimonit-21-3104]\]        2011   Turkey          STB \>15 mg/dl in the first 10 days                                                                        70           39
  Chou et al. \[[@b11-medscimonit-21-3104]\]          2011   Taiwan, China   STB \>15 mg/dl                                                                                             508          180
  Long et al. \[[@b1-medscimonit-21-3104]\]           2011   China           STB \>95% as defined by the Bhutani nomogram                                                               105          112
  Sato et al. \[[@b31-medscimonit-21-3104]\]          2012   Japan           Full-term and breast-fed neonates, STB \>10 mg/dl at day 1, \>16 mg/dl at day 3, and \>20 mg/dl at day 6   345          56
  Silva et al. \[[@b35-medscimonit-21-3104]\]         2012   India           STB \>15 mg/dl in the first 5 days                                                                         180          126
  Tiwari et al. \[[@b50-medscimonit-21-3104]\]        2013   India           STB \>95% as defined by the Bhutani nomogram                                                               100          100
  Wong et al. \[[@b9-medscimonit-21-3104]\]           2013   Malaysia        STB \>15 mg/dl                                                                                             263          52
  Travan et al. \[[@b32-medscimonit-21-3104]\]        2014   Italy           STB \>20 mg/dl                                                                                             70           70
  Tiwari et al. \[[@b30-medscimonit-21-3104]\]        2014   India           STB \>95% high-risk zone, newborns of ≤2 weeks' of age                                                     218          113
  Silva et al. \[[@b29-medscimonit-21-3104]\]         2014   India           STB ≥15 mg/dl, ≥35 weeks                                                                                   171          124

STB -- serum total bilirubin; UCB -- serum unconjugated bilirubin.

###### 

Allele frequencies of Gly71Arg UGT1A1 polymorphisms in cases of neonatal hyperbilirubinemia and controls.

  Author                    Country         Control (n)   Case (n)   A allele frequencies in control group                     
  ------------------------- --------------- ------------- ---------- --------------------------------------- ------ ----- ---- -------
  Akaba et al. 1998         Japan           76            23         2                                       18     21    3    0.134
  Maruo et al. 1999         Japan           35            14         1                                       11     11    3    0.16
  Yamamoto et al. 2002      Japan           33            15         1                                       8      12    3    0.173
  Huang et al. 2002         Taiwan, China   153           62         3                                       63     46    14   0.156
  Takeuchi et al. 2004      Japan           48            20         3                                       41     17    10   0.183
  Huang et al. 2004         Taiwan, China   80            18         2                                       35     30    7    0.11
  Sutomo et al. 2004        Malaysia        35            1          0                                       28     4     0    0.014
  Kanai et al. 2005         Japan           80            31         5                                       14     14    1    0.177
  Yusoff et al. 2005        Malaysia        47            3          0                                       52     3     0    0.03
  Ferraris et al. 2006      Italy           81            2          0                                       53     0     0    0.012
  Farheen et al. 2006       India           90            5          0                                       85     9     1    0.026
  Wong et al. 2007          Malaysia        93            31         1                                       45     18    11   0.132
  Watchko et al. 2009       America         295           4          0                                       148    4     1    0.007
  Chang et al. 2009         Taiwan, China   68            20         2                                       11     17    7    0.133
  Prachukthum et al. 2009   Thailand        80            6          0                                       68     19    4    0.035
  Kilic et al. 2010         Turkey          22            1          0                                       40     7     0    0.022
  Chou et al. 2011          Taiwan, China   367           135        6                                       111    61    8    0.145
  Long et al. 2011          China           81            22         2                                       62     39    11   0.124
  Sato et al. 2012          Japan           236           103        6                                       31     24    1    0.167
  Silva et al. 2012         India           141           39         0                                       100    26    0    0.108
  Tiwari et al. 2013        India           99            1          0                                       92     8     0    0.005
  Wong et al. 2013          Malaysia        226           22         15                                      47     4     1    0.099
  Tiwari et al. 2014        India           217           1          0                                       107    5     1    0.002
  Narter et al. 2011        Turkey          47            19         4                                       23     13    3    0.24
  Total                                     2730          598        53                                      1293   412   90   0.104

###### 

Meta-analysis of the genotyped and allele distributions of Gly71Arg UGT1A1 polymorphisms for the cases and controls.

                         GG   AA                                                     GA+AA                                                  GG+AG   AA                                                     G   A
  ---------------------- ---- ------------------------------------------------------ ------------------------------------------------------ ------- ------------------------------------------------------ --- ------------------------------------------------------
  Model                  /    Fixed                                                  Fixed                                                  /       Fixed                                                  /   Random
  Heterogeneity (I^2^)   /    22.4%                                                  49.3%                                                  /       5.8%                                                   /   55.5%
  OR (95%CI)             /    4.01 (2.47 to 6.51)                                    2.25 (1.76 to 2.87)                                    /       3.47 (2.29 to 5.28)                                    /   2.17 (1.74 to 2.72)
  P                      /    \<0.0001                                               \<0.0001                                               /       \<0.0001                                               /   \<0.0001
  Figure                 /    [Figure 1A](#f1-medscimonit-21-3104){ref-type="fig"}   [Figure 1B](#f1-medscimonit-21-3104){ref-type="fig"}   /       [Figure 1C](#f1-medscimonit-21-3104){ref-type="fig"}   /   [Figure 1D](#f1-medscimonit-21-3104){ref-type="fig"}

OR -- odds ratio; 95%CI -- 95% confidence interval.

###### 

Allele frequencies of TATA promoter UGT1A1 polymorphisms in cases of neonatal hyperbilirubinemia and controls.

  Author                 Country         Control (n)   Case (n)   (TA) 7 allele frequencies in control group                     
  ---------------------- --------------- ------------- ---------- -------------------------------------------- ----- ----- ----- -------
  Maruo et al. 1999      Japan           37            11         2                                            23    2     0     0.15
  Huang et al. 2002      Taiwan, China   165           52         1                                            102   20    1     0.124
  Seco et al. 2002       Spain           61            46         8                                            7     11    3     0.270
  Ulgenalp et al. 2003   Turkey          14            19         2                                            35    32    8     0.329
  Takeuchi et al. 2004   Japan           57            12         2                                            29    14    25    0.113
  Kanai et al. 2005      Japan           96            20         0                                            29    0     0     0.086
  Yusoff et al. 2005     Malaysia        43            6          1                                            41    10    4     0.08
  Babaoglu et al. 2006   Tukey           18            11         3                                            44    25    5     0.266
  Muslu et al. 2006      Turkey          47            7          1                                            95    12    0     0.082
  Farheen et al. 2006    India           32            53         10                                           4     15    76    0.384
  Watchko et al. 2009    America         129           127        28                                           66    62    21    0.322
  Agrawal et al. 2009    India           25            21         4                                            8     49    12    0.29
  Ergin et al. 2010      Turkey          48            6          0                                            10    34    6     0.056
  Chou et al. 2011       Taiwan, China   392           107        9                                            147   27    6     0.123
  Sato et al. 2012       Japan           254           81         10                                           49    7     0     0.146
  Tiwari et al. 2013     India           37            53         10                                           31    50    19    0.365
  Travan et al. 2014     Italy           26            30         14                                           26    31    13    0.414
  Tiwari et al. 2014     India           101           93         24                                           38    57    18    0.323
  Silva et al. 2014      India           89            63         19                                           36    63    25    0.295
  Total                                  1671          818        148                                          820   521   242   0.216

###### 

Meta-analysis of the genotyped and allele distributions of TATA promoter UGT1A1 polymorphisms for the cases and controls.

                         (TA) 6/6   (TA) 7/7                                               (TA) 6/7 + (TA) 7/7                                    (TA) 6/6 + (TA) 6/7   (TA) 7/7                                               (TA) 6   (TA) 7
  ---------------------- ---------- ------------------------------------------------------ ------------------------------------------------------ --------------------- ------------------------------------------------------ -------- ------------------------------------------------------
  Model                  /          Random                                                 Random                                                 /                     Random                                                 /        Random
  Heterogeneity (I^2^)   /          70.8%                                                  85.1%                                                  /                     73.4%                                                  /        89.2%
  OR (95%CI)             /          2.71 (1.52 to 4.82)                                    1.56 (1.02 to 2.40)                                    /                     2.24 (1.29 to 3.92)                                    /        1.51 (1.03 to 2.20)
  P                      /          0.001                                                  0.042                                                  /                     0.004                                                  /        0.035
  Figure                 /          [Figure 2A](#f2-medscimonit-21-3104){ref-type="fig"}   [Figure 2B](#f2-medscimonit-21-3104){ref-type="fig"}   /                     [Figure 2C](#f2-medscimonit-21-3104){ref-type="fig"}   /        [Figure 2D](#f2-medscimonit-21-3104){ref-type="fig"}

OR -- odds ratio; 95%CI -- 95% confidence interval.
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